Engineered Extracellular Vesicles in Chronic Kidney Diseases: A Comprehensive Review

Kaming Xue,Bobin Mi

DOI: https://doi.org/10.2147/ijn.s452393

IF: 7.033

2024-03-08

International Journal of Nanomedicine

Abstract:Kaming Xue, 1 Bobin Mi 2 1 Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China Correspondence: Bobin Mi, Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China, Email Chronic kidney diseases (CKD) present a formidable global health challenge, characterized by a deficiency of effective treatment options. Extracellular vesicles (EVs), recognized as multifunctional drug delivery systems in biomedicine, have gained accumulative interest. Specifically, engineered EVs have emerged as a promising therapeutic approach for targeted drug delivery, potentially addressing the complexities of CKD management. In this review, we systematically dissect EVs, elucidating their classification, biogenesis, composition, and cargo molecules. Furthermore, we explore techniques for EV engineering and strategies for their precise renal delivery, focusing on cargo loading and transportation, providing a comprehensive perspective. Moreover, this review also discusses and summarizes the diverse therapeutic applications of engineered EVs in CKD, emphasizing their anti-inflammatory, immunomodulatory, renoprotective, and tissue-regenerating effects. It critically evaluates the challenges and limitations in translating EV therapies from laboratory settings to clinical applications, while outlining future prospects and emerging trends. Keywords: extracellular vesicles, nanomaterials, chronic kidney diseases, drug delivery systems, application Chronic Kidney Disease (CKD) is a pervasive global health issue, marked by its significant impact on individuals and healthcare systems worldwide. 1 CKD is defined by the progressive deterioration of kidney function over time, leading to a range of complications and posing a substantial burden on affected individuals and society as a whole. The prevalence of CKD continues to rise, driven by factors such as aging populations and the increasing prevalence of conditions like diabetes and hypertension, which are major risk factors for CKD. 2 As a result, it is paramount to address the challenges associated with CKD management, as current approaches have limitations and are often unable to halt or reverse the progression of the disease. The current landscape of CKD management is fraught with several challenges. One of the foremost issues is the delayed diagnosis of CKD, as the disease often remains asymptomatic until it reaches an advanced stage. 3 This delays the initiation of therapeutic interventions, reducing their effectiveness. Furthermore, the progressive nature of CKD and the insidious development of complications, including cardiovascular disease, anemia, and bone disorders, necessitates multifaceted management approaches that can be cumbersome for both patients and healthcare providers. 4 Treatments for CKD primarily focus on symptom management, and patients with advanced CKD often require renal replacement therapy, such as dialysis or kidney transplantation, which come with their own set of challenges, including significant costs and limited availability of donor organs. In light of these challenges, there is a growing recognition of the potential of EVs as a novel approach to CKD therapy. 5 EVs, tiny vesicles secreted by various cell types, are involved in numerous physiological processes, including immune response regulation, tissue repair, and waste elimination, all of which are vital to maintain kidney health. Additionally, they play a role in pathological conditions, such as inflammation, fibrosis, and oxidative stress, which are central to CKD pathogenesis. 6 The contents of EVs in urine, including miRNAs, mRNAs, and proteins, show promise as potential biomarkers for this condition, providing a glimmer of hope for improved diagnostics and understanding of disease mechanisms. 7 The multifaceted role of EVs in kidney disease underscores their potential as therapeutic targets and diagnostic tools in this and other renal disorders. With the advances in the field of nanobiotechnology, engineered EVs have emerged as a promising therapeutic alternative for diseases. Engineered EVs exhibit several key advantages over their natural counterparts in CKD therapy. Firstly, these engineered EVs can be functionally modified to target specific kidney cells or affected areas, thus enhancing their precision and therapeutic effectiveness. For instance, engineered red blood cell-derived EVs with -Abstract Truncated-

pharmacology & pharmacy,nanoscience & nanotechnology